In conclusion, our data indicate that the likely APP-increasing effects of HLJDT on AD patients perhaps avoided by removing RS from it (i.e., HLJDT-M) and by using an appropriate ratio of RC, CP and FG. The gene discussed is CP; the disease is Alzheimer disease.